In the context of AD genetic risk based on variants with low predictive value, there is no reason to consider autonomy less valuable—any eligible testee should be in the position to autonomously decide at any time whether to know or not to know her/his genetic risk for AD (in addition to the considerations made for Mendelian neurodegenerative diseases, the uncertainty related to the limited predictive value of APOE testing should be cautiously considered). The gene discussed is APOE; the disease is Alzheimer disease.